Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C.

García-Martín E, Agúndez JA, Maestro ML, Suárez A, Vidaurreta M, Martínez C, Fernández-Pérez C, Ortega L, Ladero JM.

PLoS One. 2013 Sep 20;8(9):e74764. doi: 10.1371/journal.pone.0074764. eCollection 2013.

2.

Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C.

El-Derany MO, Hamdy NM, Al-Ansari NL, El-Mesallamy HO.

BMC Gastroenterol. 2016 Feb 24;16:19. doi: 10.1186/s12876-016-0440-5.

3.

Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C.

Hung CH, Hu TH, Lu SN, Chen CH, Wang JH, Lee CM.

J Formos Med Assoc. 2016 Apr;115(4):278-83. doi: 10.1016/j.jfma.2015.11.008. Epub 2015 Dec 22.

4.

The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.

Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Frei P, Seifert B, Bischoff Ferrari HA, von Eckardstein A, Müllhaupt B, Geier A; Swiss Hepatitis C Cohort Study Group.

Antivir Ther. 2012;17(3):541-7. doi: 10.3851/IMP2018. Epub 2011 Dec 14.

PMID:
22300961
5.

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy.

Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, Herrmann E, Badenhoop K, Zeuzem S, Sarrazin C.

J Hepatol. 2011 May;54(5):887-93. doi: 10.1016/j.jhep.2010.08.036. Epub 2011 Jan 20.

PMID:
21145801
6.

Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.

Ladero JM, Martin EG, Fernández C, Carballo M, Devesa MJ, Martínez C, Suárez A, Díaz-Rubio M, Agúndez JA.

J Gastroenterol Hepatol. 2012 Feb;27(2):279-85. doi: 10.1111/j.1440-1746.2011.06834.x.

PMID:
21722179
7.

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.

Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y.

Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14.

PMID:
24102823
8.
9.

Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia.

Cusato J, Boglione L, De Nicolò A, Cardellino CS, Carcieri C, Cariti G, Di Perri G, D'Avolio A.

Pharmacogenet Genomics. 2016 Jun;26(6):307-10. doi: 10.1097/FPC.0000000000000223.

PMID:
27139837
10.

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.

J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19.

PMID:
21129805
11.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

12.

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.

Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsuhashi H, Murakami S, Iijima S, Iio E, Sugiyama M, Shimada T, Kakuni M, Kohara M, Mizokami M.

Gut. 2013 Sep;62(9):1340-6. doi: 10.1136/gutjnl-2012-302553. Epub 2012 Nov 7.

13.

[Association of Vitamin D Receptor Polymorphisms with Response to Antiviral Therapy in Patients with Chronic Hepatitis C].

Wang C, Wu Q, Wei XT, Li ZZ, Lei XZ.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2016 Mar;47(2):227-31. Chinese.

PMID:
27263300
15.

Vitamin D pathway gene variants and HCV-2/3 therapy outcomes.

Cusato J, Allegra S, Boglione L, De Nicolò A, Baietto L, Cariti G, Di Perri G, D'Avolio A.

Antivir Ther. 2015;20(3):335-41. doi: 10.3851/IMP2853. Epub 2014 Oct 3.

PMID:
25279449
16.

Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.

Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J.

J Hepatol. 2012 Sep;57(3):534-40. doi: 10.1016/j.jhep.2012.04.027. Epub 2012 May 18.

PMID:
22613000
17.

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.

Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K.

Gut. 2011 Feb;60(2):261-7. doi: 10.1136/gut.2010.223495. Epub 2010 Nov 10.

PMID:
21068134
18.

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.

Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S.

World J Gastroenterol. 2016 Mar 28;22(12):3418-31. doi: 10.3748/wjg.v22.i12.3418.

19.

Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.

Jung YK, Kim JH, Ahn SM, Yang JW, Park SJ, Kim JW, Yeon JE, Kwon OS, Kim YS, Choi DJ, Kim JH, Byun KS.

J Clin Gastroenterol. 2013 Aug;47(7):644-50. doi: 10.1097/MCG.0b013e3182896abf.

PMID:
23442843
20.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698

Supplemental Content

Support Center